New Takeda India Leadership Amid Realignment
This article was originally published in PharmAsia News
Executive Summary
Whether or not it's a rejig in the normal course of business isn't very clear, but Japanese pharma giant Takeda has "realigned" certain teams as it pursues plans to provide sustainable access to its medicines under a new leadership in India.
You may also be interested in...
Takeda-Shire In India: Sleeping Giant?
Will Takeda take a less measured approach in India, where Shire brings it a significant on-market portfolio? Scrip outlines the current shape of things in the promising but complex emerging market as the two companies head towards combining forces globally.
Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Rivals Challenge Nintedanib In India
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.
Need a specific report? 1000+ reports available
Buy Reports